144
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer

, , , &
Pages 679-687 | Received 17 Feb 2018, Accepted 23 Apr 2018, Published online: 14 Sep 2018

References

  • Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811–820. doi:10.1016/S0140-6736(09)60484-0.
  • Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–1123. doi: 10.1056/NEJMoa060829.
  • Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–844. doi: 10.1016/S1470-2045(10)70172-8.
  • Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008;26(3):368–373. doi: 10.1200/JCO.2007.13.5434.
  • Baek SJ, Kim SH, Kwak JM, et al. Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence. World J Surg. 2013;37(1):220–226. doi: 10.1007/s00268-012-1792-9.
  • Tural D, Selcukbiricik F, Yildiz O, et al. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer. Int J Clin Oncol. 2014;19(5):889–896. doi: 10.1007/s10147-013-0636-4.
  • MERCURY Study Group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253:711–719. doi: 10.1097/SLA.0b013e31820b8d52.
  • Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753–3760. doi: 10.1200/JCO.2011.34.9068.
  • Hunter CJ, Garant A, Vuong T, et al. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment. Ann Surg Oncol. 2012;19(4):1199–1205. doi: 10.1245/s10434-011-2036-1.
  • *MERCURY Study Group. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32:34–43. doi: 10.1200/JCO.2012.45.3258.
  • Kao PS, Chang SC, Wang LW, et al. The impact of preoperative chemoradiotherapy on advanced low rectal cancer. J Surg Oncol. 2010;102(7):771–777. doi: 10.1002/jso.21711.
  • Kulu Y, Tarantino I, Billeter AT, et al. Comparative outcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer. Ann Surg Oncol. 2016;23(1):106–113. doi: 10.1245/s10434-015-4832-5.
  • Park IJ, Kim HC, Yu CS, Kim TW, Jang SJ, Kim JC. Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol. 2008;15(2):519–525. doi: 10.1245/s10434-007-9643-x.
  • Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Orthod. 2012;30(16):1926–1933. doi: 10.1200/JCO.2011.40.1836.
  • Ferenschild FT, Dawson I, de Wilt JH, de Graaf EJ, Groenendijk RP, Tetteroo GW. Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center. Int J Colorectal Dis. 2009;24(8):923–929. doi:10.1007/s00384-009-0732-0.
  • MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341(8843):457–460. doi:10.1016/0140-6736(93)90207-W.
  • Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Orthod. 2002;20(7):1729–1734. doi: 10.1200/JCO.2002.07.010.
  • Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from theMRCCR07 and NCICCTGCO16 randomised clinical trial. Lancet 2009;373(9666):821–828. doi: 10.1016/S0140-6736(09)60485-2.
  • Kang J, Kim H, Hur H, et al. Circumferential resection margin involvement in stage III rectal cancer patients treated with curative resection followed by chemoradiotherapy: a surrogate marker for local recurrence? Yonsei Med J. 2013;54(1):131–138. doi: 10.3349/ymj.2013.54.1.131.
  • Breukink SO, Grond AJ, Pierie JP, Hoff C, Wiggers T, Meijerink WJ. Laparoscopic vs open total mesorectal excision for rectal cancer: an evaluation of the mesorectum’s macroscopic quality. Surg Endosc. 2005;19(3):307–310. doi:10.1007/s00464-004-9066-8
  • Madbouly KM, Hussein AM, Abdelzaher E. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer. Am J Surg. 2014;208(3):332–341. doi: 10.1016/j.amjsurg.2013.10.023.
  • Maslekar S, Sharma A, Macdonald A, Gunn J, Monson JR, Hartley JE. Mesorectal grades predict recurrences after curative resection for rectal cancer. Dis Colon Rectum. 2007;50(2):168–175. doi: 10.1007/s10350-006-0756-2.
  • Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Orthod. 2005;23(34):8688–8696. doi: 10.1200/JCO.2005.02.1329.
  • Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):752–760. doi: 10.1016/j.ijrobp.2004.11.017.
  • Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47(11):1798–1807. doi: 10.1007/s10350-004-0681-1.
  • Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(7):2212–2223. doi: 10.1245/s10434-011-2210-5.
  • MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132–139. doi: 10.1148/radiol.2431051825.
  • Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging–a meta-analysis. Radiology 2004;232(3):773–783. doi:10.1148/radiol.2323031368.
  • Lombardi R, Cuicchi D, Pinto C, et al. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol. 2010;17(3):838–845. doi: 10.1245/s10434-009-0796-7.
  • van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–582. doi: 10.1016/S1470-2045(11)70097-3.
  • Bruheim K, Guren MG, Skovlund E, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(4):1005–1011. doi: 10.1016/j.ijrobp.2009.03.010.
  • Bosset JF, Calais G, Daban A, EORTC Radiotherapy Group et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy group. Eur J Cancer. 2004;40(2):219–224. doi: 10.1016/j.ejca.2003.09.032.
  • Picon AI, Moore HG, Sternberg SS, et al. Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3N0M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis. 2003;18(6):487–492. doi: 10.1007/s00384-003-0504-1.
  • Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Orthod. 2006;24(25):4078–4084. doi: 10.1200/JCO.2006.06.2968.
  • Steel MC, Woods R, Mackay JM, Chen F. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg. 2002;72(7):483–487. doi: 10.1046/j.1445-2197.2002.02457.x.
  • Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36(5):470–476. doi: 10.1016/j.ejso.2009.11.011.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.